NCT06683742进行中（未招募）3 期
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
- 试验地点
- 260
- 主要终点
- Average change in best corrected visual acuity (BCVA)
研究概览
简要总结
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit.
- •Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellen equivalent) in the study eye at the Screening Visit and on Baseline (Day 1).
- •For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.
排除标准
- •Subfoveal fibrosis, atrophy, or scarring in the center subfield.
- •BCVA using ETDRS charts <20 letters (20/400 Snellen equivalent) in the fellow eye.
研究组 & 干预措施
Aflibercept
Active Comparator
干预措施: Aflibercept (2.0 mg) (Drug)
EYP-1901 2686 µg
Experimental
EYP-1901
干预措施: EYP-1901 (Drug)
结局指标
主要结局
Average change in best corrected visual acuity (BCVA)
时间窗: Weeks 52 and 56
次要结局
- Rate of injection burden(Week 56)
- Average change in best corrected visual acuity (BCVA)(Week 96)
研究者
研究点 (260)
Loading locations...
相似试验
进行中（未招募）
3 期
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56NCT06668064EyePoint Pharmaceuticals, Inc.400
已完成
3 期
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular DegenerationNeovascular Age-related Macular DegenerationNCT04522167Bioeq GmbH434
招募中
3 期
S086 Tablets for Chronic Heart Failure With Reduced Ejection FractionChronic Heart Failure With Reduced Ejection FractionNCT05553886Shenzhen People's Hospital5
已完成
3 期
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)Age-related Macular DegenerationNCT00891735Genentech, Inc.1,097
已完成
3 期
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerFallopian Tube CancerPeritoneal NeoplasmsOvarian CancerNCT03038100Hoffmann-La Roche1,301